LncRNA DLX6‐AS1 increases the expression of HIF‐1α and promotes the malignant phenotypes of nasopharyngeal carcinoma cells via targeting MiR‐199a‐5p

Abstract Objective To investigate the expression of long‐chain noncoding growth stasis specific protein 6 antisense RNA1 (lncRNA DLX6‐AS1) in nasopharyngeal carcinoma (NPC) tissues and cells, and its regulatory effect on malignant phenotypes of NPC cells. Methods The expressions of DLX6‐AS1, miR‐199...

Full description

Bibliographic Details
Main Authors: Bin Yang, Lin Jia, Hui Ren, Caibao Jin, Qingrong Ren, Haiyuan Zhang, Desheng Hu, Hao Zhang, Liu Hu, Tao Xie
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Molecular Genetics & Genomic Medicine
Subjects:
Online Access:https://doi.org/10.1002/mgg3.1017
Description
Summary:Abstract Objective To investigate the expression of long‐chain noncoding growth stasis specific protein 6 antisense RNA1 (lncRNA DLX6‐AS1) in nasopharyngeal carcinoma (NPC) tissues and cells, and its regulatory effect on malignant phenotypes of NPC cells. Methods The expressions of DLX6‐AS1, miR‐199a‐5p, and HIF‐1α mRNA in NPC issues and cells were detected by qRT‐PCR. The proliferation, metastasis, and invasion of cells were monitored via MTT and transwell assay. The interactions between DLX6‐AS1 and miR‐199a‐5p, miR‐199a‐5p and HIF‐1α were verified by luciferase activity assay. Western blot was performed to determine the regulatory effect of DLX6‐AS1 and miR‐199a‐5p on HIF‐1α protein. Results The expression of lncRNA DLX6‐AS1 was up‐regulated in NPC tissues and cells. The proliferation, migration, and invasion of NPC were enhanced by overexpressed DLX6‐AS1 but inhibited by DLX6‐AS1 knockdown. In addition, DLX6‐AS1 can be used as a kind of ceRNA to regulate miR‐199a‐5p and, thereby modulating the expression of HIF‐1α. Conclusion We found that DLX6‐AS1 was a cancer‐promoting lncRNA to facilitate the progression of NPC, and its underlying mechanism was suppressing miR‐199a‐5p expression. This study can provide novel clues for the treatment of NPC.
ISSN:2324-9269